iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc. is a clinical-stage biotechnology company that develops recombinant proteins and vaccine candidates using proprietary plant-based expression systems. Headquartered in Bryan, Texas, the company leverages its Fast Expression System Technology (FAST) and LAMP™ molecular farming platforms to accelerate the design and production of complex biologics. These platforms capitalize on Nicotiana benthamiana plants as biofactories, enabling rapid, scalable expression of target proteins without the need for mammalian cell cultures.

The company’s pipeline includes vaccine candidates against viral pathogens and therapeutic proteins for immuno-oncology and infectious diseases. iBio has advanced programs targeting COVID-19, influenza and other emerging threats, while also exploring antibody-based treatments. Its technology is designed to shorten development timelines, support flexible production scales and reduce reliance on traditional fermentation systems.

In addition to its internal R&D efforts, iBio operates a wholly owned contract development and manufacturing organization (CDMO) division, iBio CDMO. Launched in 2017, this arm provides upstream and downstream process development, analytical services and commercial-scale manufacturing for third-party clients. iBio serves pharmaceutical and biotechnology customers in North America and internationally, partnering with academic institutions and industry collaborators to bring plant-derived biologics from concept through GMP production.

Key Stats

• Today's Range: $0.82 to $0.87
• 50-Day Range: $0.57 to $0.86
• 52-Week Range: N/A
• Volume: 370,082 shs
• Average Volume: 113,212 shs
• Market Capitalization: $16.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IBIO Stock Analysis - Frequently Asked Questions

How have IBIO shares performed this year?

iBio's stock was trading at $2.45 at the start of the year. Since then, IBIO shares have decreased by 66.0% and is now trading at $0.8328.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEMKT:IBIO) announced its earnings results on Monday, November, 15th. The company reported ($20.00) earnings per share for the quarter, beating the consensus estimate of ($25.00) by $5.00. The firm had revenue of $0.21 million for the quarter.

When did iBio's stock split?

Shares of iBio reverse split on the morning of Wednesday, November 29th 2023.The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), NIO (NIO), Vaxart (VXRT), Plug Power (PLUG), Tesla (TSLA), Advanced Micro Devices (AMD) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 9/10/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEMKT
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEMKT:IBIO
• CIK: 1420720
• Web: www.ibioinc.com
• Phone: (302) 355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.01 million
• Net Margins: N/A
• Pretax Margin: -41,546.00%
• Return on Equity: -150.59%
• Return on Assets: -52.83%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 0.91
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $375 thousand
• Price / Sales: 43.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.64 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 19,655,000
• Free Float: 3,445,000
• Market Cap: $16.37 million
• Optionable: N/A
• Beta: 0.86